Business Description
Neurocrine Biosciences Inc
NAICS : 325414
SIC : 2836
Compare
Compare
Traded in other countries / regions
N1BI34.Brazil
•
NB3.Germany
•
0K6R.UK
•
NBIX.USA
Description
Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 3.01 | |||||
| Equity-to-Asset | 0.72 | |||||
| Debt-to-Equity | 0.17 | |||||
| Debt-to-EBITDA | 2.44 | |||||
| Interest Coverage | 16.63 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 12.64 | |||||
| Beneish M-Score | -1.93 | |||||
| WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 34.8 | |||||
| 3-Year EBITDA Growth Rate | 33.7 | |||||
| 3-Year EPS without NRI Growth Rate | 61.1 | |||||
| 3-Year FCF Growth Rate | 43.7 | |||||
| 3-Year Book Growth Rate | 39.8 | |||||
| Future 3-5Y Total Revenue Growth Rate Industry Rank | 15.47 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 63.41 | |||||
| 9-Day RSI | 59.33 | |||||
| 14-Day RSI | 58.6 | |||||
| 6-1 Month Momentum % | 27.39 | |||||
| 12-1 Month Momentum % | 28.15 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.49 | |||||
| Quick Ratio | 2.41 | |||||
| Cash Ratio | 1.65 | |||||
| Days Inventory | 563.52 | |||||
| Days Sales Outstanding | 62.71 | |||||
| Days Payable | 959.06 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1.5 |
Profitability Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 98.59 | |||||
| Operating Margin % | 15.09 | |||||
| Net Margin % | 4.19 | |||||
| ROE % | 4.11 | |||||
| ROA % | 2.8 | |||||
| ROIC % | 13.01 | |||||
| ROC (Joel Greenblatt) % | 43.98 | |||||
| ROCE % | 5.33 | |||||
| Years of Profitability over Past 10-Year | 5 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 214.3 | |||||
| Forward PE Ratio | 30.03 | |||||
| PE Ratio without NRI | 214.3 | |||||
| PS Ratio | 8.58 | |||||
| PB Ratio | 7.6 | |||||
| Price-to-Tangible-Book | 7.6 | |||||
| Price-to-Free-Cash-Flow | 66.86 | |||||
| Price-to-Operating-Cash-Flow | 58.98 | |||||
| EV-to-EBIT | 118.24 | |||||
| EV-to-Forward-EBIT | 22.98 | |||||
| EV-to-EBITDA | 102.84 | |||||
| EV-to-Forward-EBITDA | 20.41 | |||||
| EV-to-Revenue | 8.07 | |||||
| EV-to-Forward-Revenue | 6.27 | |||||
| EV-to-FCF | 63.33 | |||||
| Price-to-Projected-FCF | 5.34 | |||||
| Price-to-Graham-Number | 8.51 | |||||
| Price-to-Net-Current-Asset-Value | 19.36 | |||||
| Price-to-Net-Cash | 58.44 | |||||
| Earnings Yield (Greenblatt) % | 0.85 |
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:NBIX
Peter Lynch Chart
Performance
Dividend
Log
Annualized Return %
Total Annual Return %
Executives
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 1,388.7 | ||
| EPS (TTM) ($) | 0.57 | ||
| Beta | 0.36 | ||
| Volatility % | 32.16 | ||
| 14-Day RSI | 58.6 | ||
| 14-Day ATR ($) | 4.088144 | ||
| 20-Day SMA ($) | 119.549 | ||
| 12-1 Month Momentum % | 28.15 | ||
| 52-Week Range ($) | 71.875 - 125.99 | ||
| Shares Outstanding (Mil) | 96.13 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Neurocrine Biosciences Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||
Neurocrine Biosciences Inc Analysis
Share your researchHeadlines
See More
No news.